X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Proceeds will be used to advance phase 1 trials of two pipeline candidates, EI-1071 and EI-001 and take three immuno-oncology assets towards IND applications .
Lead Product(s): EI-1071
Therapeutic Area: Neurology Product Name: EI-1071
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Pangu Capital
Deal Size: $27.0 million Upfront Cash: Undisclosed
Deal Type: Series A Financing August 23, 2021
Details:
Grant Program will support a U.S. FDA-approved first-in-human phase 1 clinical trial of its lead drug candidate, EI1071, an orally available, highly potent Colony-Stimulating Factor 1 Receptor (CSF1R) inhibitor.
Lead Product(s): EI1071
Therapeutic Area: Neurology Product Name: EI1071
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Alzheimer's Association
Deal Size: $1.0 million Upfront Cash: Undisclosed
Deal Type: Funding August 26, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
